Related Experiment Videos
Viral therapy for glioblastoma
E Antonio Chiocca1, Manish Aghi, Giulia Fulci
1Molecular Neuro-oncology Laboratory, Neurosurgery Service, Massachusetts General Hospital-East, Charlestown, Massachusetts 02129, USA. Chiocca@helix.mgh.harvard.edu
Cancer Journal (Sudbury, Mass.)
|September 4, 2003
Summary
Malignant gliomas are hard to treat. Viral gene therapies show promise, with improved tumor infection leading to better outcomes in clinical studies.
Area of Science:
- Oncology
- Gene Therapy
- Neuro-oncology
Background:
- Malignant gliomas represent a significant challenge in cancer treatment.
- Viral-based gene therapies have emerged as a novel therapeutic approach over the past decade.
- Preclinical and clinical studies have explored the potential of these therapies.
Purpose of the Study:
- To review and summarize the current state of viral-based gene therapies for malignant gliomas.
- To identify key factors influencing the efficacy of these novel treatments.
Main Methods:
- Literature review of preclinical and clinical studies on viral gene therapy for malignant gliomas.
- Analysis of methodologies aimed at enhancing tumor targeting and gene delivery.
Main Results:
- Viral gene therapies have been utilized for over ten years in research and clinical settings.
- Studies consistently indicate a positive correlation between increased tumor infection/transduction and therapeutic effectiveness.
- Further research is needed to optimize delivery methods.
Conclusions:
- Viral gene therapy is a promising modality for treating malignant gliomas.
- Enhancing viral transduction within tumors is critical for improving treatment outcomes.
- Future strategies should focus on optimizing infection and transduction efficiency for greater therapeutic impact.